pancreatic cancer
Conditions
Interventions
Sponsors
Oda Tatsuya
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with high suspicion of pancreatic cancer based on comprehensive imaging and pathologic evaluation. 2) Patients whose maximum diameter of suspected pancreatic cancer is less than 2.5 cm, as comprehensively assessed by imaging (CT/MRI/US). 3) Patients diagnosed at a stage where pancreatectomy can be planned without distant metastases. 4) Patients with a Karnofsky Performance Status (KPS) of 70 or higher. 5) Patients who are at least 18 years of age at the time of consent. (6) Patients who have been fully informed about the study and who have provided written informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients with serious cardiovascular disease 2) Patients with serious respiratory disease 3) Patients with serious hepatic disease (AST (GOT) or ALT (GPT) > 100 U/L) 4) Patients with serious renal disease (BUN > 25 mg/dL or serum creatinine > 2.0 mg/dL) 5) Women who are pregnant or have the possibility or desire to become pregnant 6) Women in the lactation period 7) Patients undergoing treatment for upper abdominal malignancies, or patients with a history of treatment for upper abdominal malignancies 8) Patients with phenylketonuria 9) Other patients who are deemed inappropriate as subjects by the principal investigator (subinvestigator).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ability to detect the main lesion (primary lesion) of pancreatic cancer compared to conventional imaging examinations | — |
Secondary
| Measure | Time frame |
|---|---|
| 18F-FAPI PET scan ability to detect the main lesion of pancreatic cancer (primary lesion) compared to FDG PET scan Detection of metastatic foci of pancreatic cancer compared to FDG-PET scan Detection of pancreatic cancer metastasis compared to conventional imaging Correlation of immunohistologic evaluation of fibrosis and FAP in surgical specimens Correlation between 18F-FAPI PET uptake (SUV value) and blood tumor markers Correlation of 18F-FAPI PET accumulation (SUV value) with molecular biological analysis of surgical specimens | — |
Contacts
Public ContactMiyazaki Yoshihiro
University of Tsukuba Hospital
Outcome results
None listed